Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shima Mimura

Showing results (11-20 of 58) with videos related to

Pageof 6
Sort By:
Cancer Medicine|December 8, 2023
Efficacy and outcome of molecular targeted therapies in elderly patients with hepatocellular carcinoma: Relative dose intensity associated with overall survivalKyoko Oura, Asahiro Morishita, Kei Takuma, et al.
Anticancer Research|June 27, 2025
The Polyphenol (-)-Epigallocatechin-3-gallate (EGCG) Inhibits the Proliferation of Gastric Cancer Cells and Alters microRNA SignaturesKota Sasaki, Koji Fujita, Shintaro Fujihara, et al.
Internal and Emergency Medicine|January 27, 2021
Effect of pegylated interferon alfa-2a in HBeAg-negative chronic hepatitis B during and 48 weeks after off-treatment follow-up: the limitation of pre-treatment HBsAg load for the seroclearance of HBsAgShima Mimura, Koji Fujita, Kei Takuma, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|May 9, 2026
Widespread Muscle Loss in Autoimmune Hepatitis and Its Adverse Prognostic ImpactTomoko Tadokoro, Asahiro Morishita, Takushi Manabe, et al.
Experimental and Therapeutic Medicine|November 29, 2023
Predictors of therapeutic response to peginterferon α‑2a and nucleos(t)ide analog combination therapy for HBeAg‑negative chronic hepatitis B: 1‑year follow‑up after treatmentShima Mimura, Koji Fujita, Kei Takuma, et al.
Journal of Clinical Medicine|December 11, 2025
Autoantibodies in Primary Biliary Cholangitis: From Classical Markers to Emerging TargetsShima Mimura, Asahiro Morishita, Kyoko Oura, et al.
Nutrients|February 13, 2026
Optimizing Nutrition to Counter Sarcopenia in Hepatocellular Carcinoma: A Narrative Review of Mechanisms, Clinical Consequences, and Supportive Therapeutic OptionsHiroki Tai, Asahiro Morishita, Tomoko Tadokoro, et al.
Cancers|February 27, 2026
Advances in the Therapeutic Landscape of Hepatocellular Carcinoma: Current Strategies and Future PerspectivesAsahiro Morishita, Kyoko Oura, Hiroki Tai, et al.
Cancers|March 29, 2023
Prognostic Value of Skeletal Muscle Loss in Patients with Hepatocellular Carcinoma Treated with Hepatic Arterial Infusion ChemotherapyKyoko Oura, Asahiro Morishita, Joji Tani, et al.
BMC Gastroenterology|April 2, 2024
Management of hepatocellular carcinoma, an important cause of death in Japanese autoimmune hepatitis patientsTomoko Tadokoro, Takako Nomura, Koji Fujita, et al.
Pageof 6

Showing results (11-20 of 58) with videos related to

Sort By:
Pageof 6
Cancer Medicine|December 8, 2023
Efficacy and outcome of molecular targeted therapies in elderly patients with hepatocellular carcinoma: Relative dose intensity associated with overall survivalKyoko Oura, Asahiro Morishita, Kei Takuma, et al.
Anticancer Research|June 27, 2025
The Polyphenol (-)-Epigallocatechin-3-gallate (EGCG) Inhibits the Proliferation of Gastric Cancer Cells and Alters microRNA SignaturesKota Sasaki, Koji Fujita, Shintaro Fujihara, et al.
Internal and Emergency Medicine|January 27, 2021
Effect of pegylated interferon alfa-2a in HBeAg-negative chronic hepatitis B during and 48 weeks after off-treatment follow-up: the limitation of pre-treatment HBsAg load for the seroclearance of HBsAgShima Mimura, Koji Fujita, Kei Takuma, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|May 9, 2026
Widespread Muscle Loss in Autoimmune Hepatitis and Its Adverse Prognostic ImpactTomoko Tadokoro, Asahiro Morishita, Takushi Manabe, et al.
Experimental and Therapeutic Medicine|November 29, 2023
Predictors of therapeutic response to peginterferon α‑2a and nucleos(t)ide analog combination therapy for HBeAg‑negative chronic hepatitis B: 1‑year follow‑up after treatmentShima Mimura, Koji Fujita, Kei Takuma, et al.
Journal of Clinical Medicine|December 11, 2025
Autoantibodies in Primary Biliary Cholangitis: From Classical Markers to Emerging TargetsShima Mimura, Asahiro Morishita, Kyoko Oura, et al.
Nutrients|February 13, 2026
Optimizing Nutrition to Counter Sarcopenia in Hepatocellular Carcinoma: A Narrative Review of Mechanisms, Clinical Consequences, and Supportive Therapeutic OptionsHiroki Tai, Asahiro Morishita, Tomoko Tadokoro, et al.
Cancers|February 27, 2026
Advances in the Therapeutic Landscape of Hepatocellular Carcinoma: Current Strategies and Future PerspectivesAsahiro Morishita, Kyoko Oura, Hiroki Tai, et al.
Cancers|March 29, 2023
Prognostic Value of Skeletal Muscle Loss in Patients with Hepatocellular Carcinoma Treated with Hepatic Arterial Infusion ChemotherapyKyoko Oura, Asahiro Morishita, Joji Tani, et al.
BMC Gastroenterology|April 2, 2024
Management of hepatocellular carcinoma, an important cause of death in Japanese autoimmune hepatitis patientsTomoko Tadokoro, Takako Nomura, Koji Fujita, et al.
Pageof 6